BiDil(R) Data to be Presented at Heart Failure Society of America Science Meeting

NitroMed, Inc. (NASDAQ: NTMD), an emerging pharmaceutical company and the maker of BiDil® (the fixed dose combination of isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, said today that five abstracts will be presented at the 11th Annual Scientific Meeting of the Heart Failure Society of America taking place September 16-19, 2007 in Washington, DC. "This new information helps broaden our clinical understanding of BiDil by adding to the body of evidence that BiDil represents important adjunct therapy in the treatment of black heart failure patients. These latest data about BiDil’s efficacy to improve survival in high risk heart failure patients with atrial fibrillation, its use in the elderly, its use with concomitant therapies, and the genetic results, expand our understanding of BiDil’s effects in younger and aging patients with different concomitant diseases and heart failure medications,” said Manuel Worcel, MD, NitroMed’s Chief Medical Officer. The abstracts to be presented are: 1. Mitchell JE, Tam SW, Trivedi K, Sabolinski ML and Worcel M. Atrial Fibrillation and Mortality in Patients Enrolled in the African American Heart Failure Trial. HFSA 2007. 2. Taylor AL, Sabolinski ML, Tam SW, Worcel M, Cohn JN. Fixed-dose combined isosorbide dinitrate/hydralazine improves outcomes in elderly heart failure patients in the African-American Heart Failure Trial. HFSA 2007. 3. Ghali JK, Tam SW, Mitchell JE, Sabolinski ML, Worcel M. Role of Digitalis in the Contemporary Management of Systolic Heart Failure in African Americans. HFSA 2007. 4. Rame EJ, Tam W, McNamara DM, Worcel M, Sabolinski ML, Dries DL. Prognostic Import of the Corin I555(P568) Allele in African-Americans with Moderate to Severe Heart Failure: Results from the A-HeFT Trial. HFSA 2007. 5. Sardar MR, Kezerashvili A, Galvao M, Maybaum S, Trivedi K, Shin JJ. Optimization of Medical Therapy in African-American Patients with Heart Failure Referred for Cardiac Resynchronization Therapy. HFSA 2007 About NitroMed, Inc. NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company’s landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization. For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc. Forward Looking Statements Statements in this press release about future expectations, plans and prospects for the Company, including the Company’s positioning to achieve the Company’s goals and objectives, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks discussed in the Section titled "Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, which has been filed with the SEC, and in the other filings that the Company makes with the SEC from time to time. The forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.